Day: November 17, 2021

VICTOR F. “TREY” TRAHAN, III, FAIA, SELECTED AS THE 2021 LAUREATE OF THE AMERICAN PRIZE FOR ARCHITECTURE BY BOTH THE CHICAGO ATHENAEUM: MUSEUM OF ARCHITECTURE AND DESIGN AND THE EUROPEAN CENTRE FOR ARCHITECTURE ART DESIGN AND URBAN STUDIES

New Orleans, LA /New York, NY, Nov. 16, 2021 (GLOBE NEWSWIRE) — New Orleans, LA/ New York, NY –Trahan Architects, a global architecture firm with studios in New Orleans and New York City, announced today that its founder and CEO, Victor F. “Trey” Trahan, III, FAIA, has been selected as

Read more

CNH Industrial to announce an Iveco Group Investor Day on November 18, 2021

ADVERTISEMENT. This announcement is an advertisement for the purposes of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”) relating to the intention of the Company to proceed with the admission to listing and trading on Euronext Milan of all Iveco Group N.V. common shares (the “Admission”). This announcement does not

Read more

The E-Gift Cards Giant GiftChill to Accept Dogecoin as Payment

GiftChill announces they are going to be accepting Dogecoin on the e-gift card platform. Adding Dogecoin benefits the millions of Dogecoin investors looking for ways to use their cryptocurrency. GiftChill has built a successful pathway for crypto investors to convert currency for use with retailers who do not accept cryptocurrency

Read more

HostDime Buys Land in Guadalajara, Mexico for New Tier IV Data Center

HostDime Mexico Tier IV Data Center GUADALAJARA, Mexico, Nov. 16, 2021 (GLOBE NEWSWIRE) —  HostDime is excited to announce another addition to its purpose-built, next-gen, public data center portfolio with the purchase of a three-acre land parcel in Guadalajara, Mexico. With an estimated completion date of Q4 2023, this will

Read more

Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines

SAN DIEGO and BASEL, Switzerland, Nov. 16, 2021 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, Inc., a biotechnology company developing next-generation cytokine immunotherapies, today announced that it has entered into a license agreement with Livzon Mabpharm, Inc. (“Livzon”), a subsidiary company of Livzon Pharmaceutical Group, to use LZM009, Livzon’s proprietary anti-PD-1

Read more

Recent News